Ocuphire Pharma Results Presentation Deck

CO 6 APX3330 History and Ref-1 Inhibition Mechanism Ref-1 Involved in Multiple Key Pathways that Contribute to Diabetic Retinopathy and DME Mechanism of Action - Ref-1 Inhibition Нурохіа ↓ Ref-1 HIF-1a VEGF (Signaling Cascade) Anti-VEGF Lucentis® EYLEAⓇ APX3330 — Neovascularization Logsdon et al (2018), Li et al (2014). Inflammation Ref-1 NF-kB TNF-a Chemokines Other Growth Factors (Signaling Cascade) Steroids ● • Ref-1 (reduction-oxidation effector factor-1) is a novel target discovered by Dr. Mark R. Kelley at Indiana University School of Medicine and Ocuphire's Scientific Advisor for APX program ● APX3330 is a small molecule oral drug candidate and a first-in-class inhibitor of Ref-1 • APX3330 previously developed by Eisai for multiple hepatic inflammatory indications and later by Apexian for advanced solid tumors in 11 Phase 1 and 2 trials Similar oncology origin as approved anti-VEGFs ● MOA uniquely decreases both abnormal angiogenesis and inflammation by blocking pathways downstream of Ref-1 Extensively studied in over 20 in-vitro and animal studies with favorable efficacy and safety Ocuphire PHARMA

View entire presentation